Highlights
This large observational cohort study of over 55,000 patients with chronic obstructive pulmonary disease reveals that umeclidinium-vilanterol demonstrates superior effectiveness in preventing COPD exacerbations compared to other LAMA-LABA fixed-dose combinations. The findings support once-daily dry powder inhaler therapy as a preferred first-line dual bronchodilator option for symptomatic COPD patients.
Key findings include a 14% reduction in exacerbation risk with umeclidinium-vilanterol versus glycopyrrolate-formoterol, a 3% reduction versus tiotropium-olodaterol, with comparable cardiovascular and respiratory safety across all treatments.